Another testing post – jetpack functionalities disabled
this is an excerpt
Author byline test
What is Lorem Ipsum?
Heard at HLTH: Altera Digital Health
Chief Medical Officer, Dr. Mark Pratt of Altera Digital Health addresses the way technology can be leveraged to improve healthcare in rural communities.
Featured story testing process
This is a test for a featured story while publishing
presented by
Only 5 Supreme Court Justices Believe In The Supremacy Clause And That’s A Real Fricking Problem
Testing the excerpt here
MedCity News is Accepting Applications for the Healthcare Startup Pitch Perfect Contest in Chicago
Each track will spotlight a different specialty area including: oncology, cardiology, women's health and preventing burnout/supporting operational efficiency.
At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy
Though GSK divested much of its oncology assets to Novartis in 2015, the company has built back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P. Morgan Healthcare Conference in San Francisco.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
What Was the Most-Repeated Word in CVS Health CEO’s JPM Presentation?
The word has gained greater urgency in recent years as the consumer trend in healthcare has forced payers, providers and all other kinds of healthcare stakeholders to swear by it.
J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition
Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the investment bank said big pharmas are looking for deals involving de-risked assets.
With Phase 3 Studies Ongoing in Bladder Cancer, CG Oncology Plots Course for IPO
CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follow the report of interim efficacy data showing a 75% complete response rate.
Pandemic Preparedness for CDMOs: Will It Be Different Next Time?
Contract development and manufacturing organizations cannot develop or distribute vaccines alone, but through partnerships, their infrastructure can provide the foundation for delivering life-saving tools swiftly and equitably when a new public health crisis emerges.
QA – Heard at HLTH: Cohere Health
Life science startups account for just 8% of global startups but are the second largest driver of investment capital, according to a 2022 report. Cell and gene therapies, machine learning technologies and other innovations have spurred the growth of life science companies. But the life science sector gained attention during the Covid-19 pandemic in a way […]
Goldman Sachs Closes $650M Fund to Invest in ‘Golden Era’ of Biotech Innovation
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.
Longboard Pharma Trial Data Show How It Could Stand Out in the Epilepsy Field
Longboard Pharmaceuticals’ epilepsy drug candidate bexicaserin met the main efficacy goal of its Phase 1b/2a study along with safety data suggesting a potential edge over current treatments. With Longboard now preparing to advance to Phase 3 testing, its stock price soared more than 300%.
Novartis Returns to Voyager Therapeutics to Reach New Gene Therapy Destinations
Novartis is paying Voyager Therapeutics $100 million up front to collaborate on gene therapies for Huntington’s disease and spinal muscular atrophy. The deal builds on a relationship the companies started in 2022.
Are Rare Brain Diseases the Next Commercial Frontier for Gene Therapy?
The biggest trend in gene therapy development is the potential of several treatments for rare neurological diseases to move from the bench to the bedside.
Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.